Canterbury DHB
This is a rare subtype of ALL (<5%). With intensive chemotherapy (e.g., LY10) survival in Burkitt Leukaemia and Lymphoma, i.e., patients with extensive disease, is more than 50%. In Burkitt Lymphoma allografting could be considered if CR is not achieved after the first 2 cycles of chemotherapy (Codox M and IVAC). Autografting could be considered in that situation if allografting is not practicable, and the disease can be controlled by another type of chemotherapy.
Topic Code: 8151